现代目标温度管理试验中的体温变异性
本研究基于Eurotherm3235多中心随机对照试验数据,纳入386例创伤性脑损伤后颅内压升高的患者,分析随机化后48小时内及7天内核心体温变异性与6个月扩展格拉斯哥结局量表(GOSE)的关系。采用平均移动极差将体温变异性分三分位,以序数逻辑回归校正基线协变量和治疗效应。结果显示,仅48小时内高体温变异性与更差的GOSE相关,且仅在对照组中仍具统计学显著性;低温组48小时内及两组7天内均未见统计学显著效应。作者结论认为,在目标体温正常时,体温变异性在校正基线协变量的序数分析中可能具有统计学显著性。
要点
- 研究纳入386例Eurotherm3235试验患者,分析随机化后48小时内核心体温变异性与6个月GOSE的关系。
- 48小时内高体温变异性与更差的扩展格拉斯哥结局量表评分相关,校正基线协变量和治疗效应后仍具统计学显著性。
- 该效应仅在对照组中分析时仍具统计学显著性,在低温组48小时内未见统计学显著效应。
- 7天内体温变异性在两组中均未见统计学显著效应。
- 作者结论:目标体温正常时,体温变异性在校正基线协变量的序数分析中可能具有统计学显著性。
适用人群与场景
- 纳入Eurotherm3235试验的创伤性脑损伤后颅内压升高患者,随机接受治疗性低温联合标准治疗或仅标准治疗。
- 研究场景为18个国家47个重症监护单元。
研究设计与关键结果
- 研究类型为基于多中心随机对照试验的二次分析,纳入386例患者,来自18个国家47个重症监护单元。
- 主要结局为随机化后6个月扩展格拉斯哥结局量表(GOSE)折叠评分。
- 采用平均移动极差将随机化后48小时内和7天内核心体温变异性分三分位。
- 48小时内高体温变异性与更差的GOSE相关,校正基线协变量和治疗效应后仍具统计学显著性。
- 仅分析对照组时,48小时内高体温变异性与更差GOSE的关联仍具统计学显著性。
- 低温组48小时内及两组7天内体温变异性与GOSE的关联均未见统计学显著性。
证据类型、等级与局限
- 证据类型:基于多中心随机对照试验的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在目标体温正常时,体温变异性在校正基线协变量的序数分析中可能具有统计学显著性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The Eurotherm3235 trial showed that therapeutic hypothermia was deleterious in patients with raised intracranial pressure following traumatic brain injury. We sought to ascertain if increased temperature variability within the first 48 hours, or for 7 days post randomization, were modifiable risk factors associated with poorer outcome.
DESIGN: Eurotherm3235 was a multicenter randomized controlled trial. Patients were randomized to receive either therapeutic hypothermia in addition to standard care or the later only. Mean moving range (mr) was used to stratify subjects into tertiles by the variability present in their core temperature within the first 48 hours post randomization and within 7 days post randomization. The primary outcome measure was a collapsed Glasgow Outcome Scale-Extended at 6 months post randomization. The temperature variability effect was estimated with ordinal logistic regression adjusted for baseline covariates and treatment effect.
SETTING: Forty-seven critical care units in 18 countries.
PATIENTS: Patients enrolled in the Eurotherm3235 trial to either therapeutic hypothermia or control treatments only.
MEASUREMENTS AND MAIN RESULTS: Three hundred eighty-six patients were included in our study. High level of temperature variability during the first 48 hours was associated with poorer collapsed Glasgow Outcome Scale-Extended. This effect remained statistically significant when only the control arm of the study was analyzed. No statistically significant effect was seen within the first 48 hours in the hypothermia group or within 7 days in either group.
CONCLUSIONS: When targeting normothermia, temperature variability may be a statistically significant variable in an ordinal analysis adjusted for baseline covariates.
参考来源
- Abu-Arafeh A, Rodriguez A, Paterson RL, et al. Temperature Variability in a Modern Targeted Temperature Management Trial. Crit Care Med. 2018. PMID: 29135501. doi:10.1097/CCM.0000000000002832
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。